https://scholars.lib.ntu.edu.tw/handle/123456789/528561
標題: | High burden of antimicrobial resistance in Asia | 作者: | Jean S.-S. PO-REN HSUEH |
公開日期: | 2011 | 卷: | 37 | 期: | 4 | 起(迄)頁: | 291-295 | 來源出版物: | International Journal of Antimicrobial Agents | 摘要: | Antimicrobial resistance is associated with high mortality rates and high medical costs. Marked variations in the resistance profiles of bacterial and fungal pathogens as well as the quality of public hygiene have had a considerable impact on the effectiveness of antimicrobial agents in Asian countries. In Asia, one of the epicentres of antimicrobial drug resistance, there is an alarming number of antibiotic-resistant species, including penicillin- and erythromycin-resistant Streptococcus pneumoniae, ampicillin-resistant Haemophilus influenzae, multidrug-resistant (MDR) Acinetobacter baumannii, extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae (particularly mediated by CTX-M-9, CTX-M-14 and CTX-M-15), New Delhi metallo-β-lactamase 1 (NDM-1)-producing Enterobacteriaceae, MDR Salmonella enterica serotypes Choleraesuis and Typhi, carbapenem-resistant A. baumannii (OXA-58 and OXA-23 carbapenemases) and azole-resistant Candida glabrata. A few clones of MDR A. baumannii and hospital-acquired meticillin-resistant Staphylococcus aureus (MRSA) have been widely disseminated in hospital settings in Asia, and K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains have been widely distributed in China. In addition, the emergence of extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) has illustrated the need for regular monitoring of resistance profiles of clinical isolates as well as the deliberative use of fluoroquinolones. Continuous surveillance of resistance data from clinical isolates as well as implementation of strict infection control policies in healthcare settings are required to mitigate the progression of antimicrobial resistance. ? 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/528561 | ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2011.01.009 | SDG/關鍵字: | amikacin; amphotericin B; ampicillin; capreomycin; carbapenem derivative; ceftriaxone; colistin; cotrimoxazole; erythromycin; fluconazole; imipenem; isoniazid; kanamycin; meropenem; nalidixic acid; penicillin G; Pneumococcus vaccine; polymyxin B; quinoline derived antiinfective agent; rifampicin; sultamicillin; tetracycline; typhoid vaccine; vancomycin; Acinetobacter; Acinetobacter baumannii; antibiotic resistance; antibiotic sensitivity; antifungal resistance; Asia; bacterial strain; Candida glabrata; China; Enterobacteriaceae; Haemophilus influenzae; human; Klebsiella pneumoniae; methicillin resistant Staphylococcus aureus; minimum inhibitory concentration; Moraxella catarrhalis; multidrug resistance; Mycobacterium tuberculosis; nonhuman; pneumococcal infection; priority journal; Pseudomonas aeruginosa; review; Salmonella choleraesuis; Salmonella typhi; Staphylococcus aureus; Streptococcus pneumoniae; typhoid fever; vaccination; vancomycin resistant Enterococcus |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。